FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

ALPHA LIPOIC ACID AS ADD-ON THERAPY TO SUBCUTANEOUS INTERFERON Β-1A FOR RELAPSING-REMITTING MS: STUDY

































Alpha Lipoic Acid
Image Source: LIMITLESSSHOT


ABSTRACT

Objectives:
Treatment of relapsing-remitting multiple sclerosis (RRMS) with interferon (IFN) β-1a is only partially effective in reducing relapses and progression of disability. Alpha lipoic acid (ALA)–a naturally occurring compound that is essential in energy metabolism−has been shown to exert significant anti-inflammatory, antioxidant, and neuroprotective effects. We designed the current pilot study to assess the efficacy of ALA as add-on therapy to subcutaneous (sc) IFN β-1a
in RRMS patients.

Methods:
We enrolled 13 patients with RRMS in a 2-year, placebo-controlled, double-blind, randomized trial of ALA (400 mg given orally twice daily for the first year and 200 mg twice daily for the second year) as add-on treatment to sc
IFN β-1a (44 μg, three times weekly). After starting treatment with sc IFN β-1a, patients were randomly assigned to ALA (n = 7) or placebo (n = 6) for two years. Changes in clinical measures from baseline to the end of the study served as the primary outcome for analysis, whereas secondary outcomes were modifications in MRI parameters.

Results:
At the end of follow-up, no significant between-group differences were observed for both changes in clinical
measures and MRI parameters.

Conclusions:
Although we found no beneficial effect of ALA as add-on therapy to sc IFN β-1a in RRMS patients, our pilot results should be interpreted cautiously because of the small sample size. Future larger studies are needed to investigate whether higher ALA doses could be beneficial.

Story Source: The above story is based on materials provided by INTERNATIONALJOURNALOFAPPLIEDBIOLOGYANDPHARAMACEUTICALTECHNOLOGY
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News